| 5.74 0.1 (1.77%) | 10-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.15 | 1-year : | 7.59 |
| Resists | First : | 6.12 | Second : | 6.5 |
| Pivot price | 5.91  |
|||
| Supports | First : | 5.51 | Second : | 4.58 |
| MAs | MA(5) : | 5.79 |
MA(20) : | 5.95 |
| MA(100) : | 4.71 |
MA(250) : | 4.42 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 19.1 |
D(3) : | 26.4 |
| RSI | RSI(14): 49.6 |
|||
| 52-week | High : | 6.5 | Low : | 3.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ OBIO ] has closed above bottom band by 28.2%. Bollinger Bands are 16.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.85 - 5.89 | 5.89 - 5.92 |
| Low: | 5.58 - 5.62 | 5.62 - 5.66 |
| Close: | 5.68 - 5.74 | 5.74 - 5.8 |
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
Thu, 15 Oct 2026
Orchestra BioMed Stock Has A Clearer Trial Timeline But A Demanding Valuation (OBIO) - Seeking Alpha
Sat, 03 Oct 2026
Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO) and Regeneron (REGN) - The Globe and Mail
Thu, 01 Oct 2026
After three 15,000-share sales, Sherman proposes another at Orchestra BioMed (OBIO). - Stock Titan
Thu, 01 Oct 2026
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy - GlobeNewswire
Thu, 01 Oct 2026
A pacemaker therapy trial for hard-to-control blood pressure enrolled 330 people - Stock Titan
Mon, 21 Sep 2026
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 3.296e+007 (%) |
| Held by Institutions | 24.4 (%) |
| Shares Short | 2,460 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.764e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -184.7 % |
| Operating Margin | -25 % |
| Return on Assets (ttm) | 404.5 % |
| Return on Equity (ttm) | -45.8 % |
| Qtrly Rev. Growth | 3.198e+007 % |
| Gross Profit (p.s.) | -172.12 |
| Sales Per Share | -764.04 |
| EBITDA (p.s.) | 6.11923e+007 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 9.32 |
| Dividend | 0 |
| Forward Dividend | 2.55e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|